Preformed and de novo DSA are associated with T-cell-mediated rejection in pediatric liver transplant recipients requiring clinically indicated liver biopsy.
Banff criteria
T-cell
donor-specific antibody
graft survival
mean fluorescence intensity
mediated rejection
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
06
02
2019
revised:
07
09
2019
accepted:
26
09
2019
pubmed:
5
11
2019
medline:
26
1
2021
entrez:
5
11
2019
Statut:
ppublish
Résumé
Despite growing interest about the impact of donor-specific HLA antibodies (DSA) in LT limited data are available for pediatric recipients. Our aim was to perform a retrospective single-center chart review of children (0-16 years) having undergone LT between January 1, 2005 and December 31, 2017, to characterize DSA, to identify factors associated with the development of de novo DSA, and to analyze potential associations with the diagnosis of TCMR. Information on patient- and donor-characteristics and LB reports were analyzed retrospectively. Serum obtained before LT and at LB was analyzed for presence of recipient HLA antibody using Luminex
Substances chimiques
Biomarkers
0
HLA Antigens
0
Isoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13611Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Fontana M, Moradpour D, Aubert V, Pantaleo G, Pascual M. Prevalence of anti-HLA antibodies after liver transplantation. Transpl Int. 2010;23(8):858-859.
O'Leary JG, Kaneku H, Susskind BM, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Postliver transplant. Am J Transplant. 2011;11(9):1868-1876.
O'Leary JG, Kaneku H, Jennings L, et al. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl. 2013;19(9):973-980.
O'Leary J, Demetris A, Friedman L, et al. The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant. 2014;14(4):779-787.
O'Leary J, Kaneku H, Banuelos N, Jennings L, Klintmalm G, Terasaki P. Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am J Transplant. 2015;15(4):1003-1013.
Kim P, Demetris A, O'Leary J. Prevention and treatment of liver allograft antibody-mediated rejection and the role of the ‘two-hit hypothesis’. Curr Opin Organ Transplant. 2016;21(2):209-218.
Grabhorn E, Binder T, Obrecht D, et al. Long-term clinical relevance of de novo donor-specific antibodies after pediatric liver transplantation. Transplantation. 2015;99(9):1876-1881.
Sundaram S, Melin-Aldana H, Neighbors K, Alonso E. Histologic characteristics of late cellular rejection, significance of centrilobular injury, and long-term outcome in pediatric liver transplant recipients. Liver Transpl. 2006;12(1):58-64.
Tokodai K, Nawagishi N, Miyagi S, et al. The significance of screening for HLA antibodies in the long-term follow-up of pediatric liver transplant recipients. Transpl Proc. 2016;48(4):1139-1141.
Couchonnal E, Rivet C, Ducreux S, Dumortier J, Bosch A, Boillot O. Deleterious impact of C3d-binding donor-specific anti-HLA antibodies after pediatric liver transplantation. Transpl Immunol. 2017;45:8-14.
Nankivell B, Alexander S. Rejection of the kidney allograft. N Engl J Med. 2010;363(15):1451-1462.
Kim JJ, Balasubramanian R, Michaelides G, et al. The clinical spectrum of de novo donor-specific antibodies in pediatric renal transplant recipients. Am J Transplant. 2014;14(10):2350-2358.
Campbell P. Clinical relevance of human leukocyte antigen antibodies in liver, heart, lung and intestine transplantation. Curr Opin Organ Transplant. 2013;18(4):463-469.
Demetris A, Bellamy C, Hübscher S, et al. 2016 Comprehensive update of the banff working group on liver allograft pathology: introduction of antibody-mediated rejection. Am J Transplant. 2016;16(10):2816-2835.
Demetris A, Batts P, Dhillon A, et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology. 1997;25(3):658-663.
Varma S, Ambroise J, Latinne D, et al. Progressive fibrosis is driven by genetic predisposition, allo-immunity, and inflammation in pediatric liver transplant recipients. EBioMedcine. 2016;9:346-355.
Tokodai K, Miyagi S, Nakanishi C, Hara Y, Nakanishi W, Unno M. Effect of recipient age at liver transplantation on prevalence of post-transplant donor-specific HLA antibody. Ann Transplant. 2017;2(22):333-337.
Wozniak L, Hickey M, Venick R, et al. Donor-specific HLA antibodies are associated with late allograft dysfunction after pediatric liver transplantation. Transplantation. 2015;99(7):1416-1422.
Markiewicz-Kijewska M, Kaliciński P, Kluge P, Piątosa B, Rękawek A, Jankowska I. Antibody-mediated rejection in pediatric liver transplant recipients. Ann Transplant. 2014;4(19):119-123.
Dao M, Habès D, Taupin J, Mussini C, Redon M, Superbielle C. Morphological characterization of chronic antibody-mediated rejection in ABO-identical or ABO-compatible pediatric liver graft recipients. Liver Transplant. 2018;24:897-907.
Goldberg D, Levitsky J, Shaked A. Incidence of acute cellular rejection post-transplantation and its impact on long-term graft and patient survival. Hepatology. 2015;1:210A.
Hirata Y, Yoshizawa A, Egawa H, et al. Impact of antibodies that react with liver tissue and donor-specific anti-HLA antibodies in pediatric idiopathic posttransplantation hepatitis. Transplantation. 2017;101(5):1074-1083.
Worthington JE, Robson AJ, Sheldon S, Langton A, Martin S. A comparison of enzyme-linked immunoabsorbent assays and flow cytometry techniques for the detection of HLA specific antibodies. Hum Immunol. 2001;62(10):1178-1184.
Cuadrado A, San Segundo D, López-Hoyos M, Fábrega E. Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation. World J Gastroenterol. 2015;21(39):11016-11026.
Gebel H, Harris S, Bray R. Conundrums with FlowPRA beads. Clin Transplant. 2002;16(Suppl 7):24-29.
Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen anti- bodies in pediatric late liver allografts. Liver Transpl. 2012;18(11):1333-1342.
Waki K, Sugawara Y, Mizuta K, et al. Predicting operational tolerance in pediatric living-donor liver transplantation by absence of HLA antibodies. Transplantation. 2013;95(1):177-183.
Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Kamar N. Donor-specific antibodies and liver transplantation. Hum Immunol. 2016;77(11):1063-1070.
Kivelä J, Kosola S, Peräsaari J, et al. Donor-specific antibodies after pediatric liver transplantation: a cross-sectional study of 50 patients. Transpl Int. 2016;29(4):494-505.
Levitsky J, Kaneku H, Jie C, Tambur AR. Donor-specific HLA antibodies in living versus deceased donor liver transplant recipients. Am J Transplant. 2016;16(8):2437-2444.
Wozniak L, Naini B, Hickey M, et al. Acute antibody-mediated rejection in ABO-compatible pediatric liver transplant recipients: case series and review of the literature. Pediatr Transplant. 2017;21(1):1-13.
Kaneku H, O'Leary JG, Banuelos N, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant. 2013;13(6):1541-1548.
Iacob S, Cicinnati V, Lindemann M, et al. Donor-specific anti-HLA antibodies and endothelial C4d deposition-association with chronic liver allograft failure. Transplantation. 2015;99(9):1869-1875.
Feng S, Bucuvalas J, Demetris A, et al. Evidence of chronic allograft injury in liver biopsies from long-term pediatric recipients of liver transplants. Gastroenterology. 2018;155(6):1838-1851.e7.
Ueno T, Zenitani H, Yamanaka H, et al. Impact of donor-specific antibodies on graft fibrosis after pediatric living donor liver transplantation for biliary atresia. Transplant Proc. 2016;48(4):1095-1099.
Taner T, Stegall M, Heimbach J. Antibody-mediated rejection in liver transplantation: current controversies and future directions. Liver Transpl. 2014;20(5):514-527.
Locke J, Zachary A, Warren D, et al. Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant. 2009;9(9):2136-2139.
Castillo-Rama M, Jose Castro M, Bernardo I, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility. Liver Transpl. 2008;14(4):554-562.
Kim H, Yi N-J, Song EY, et al. Preformed donor-specific antibodies do not affect the 1-year allograft survival in living donor liver transplantation. Clin Transplant. 2018;32(5):e13244.
Taner T, Gandhi M, Sanderson S, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant. 2012;12(6):1504-1510.
Ferrandiz I, Congy-Jolivet N, Del Bello A, et al. Impact of early blood transfusion after kidney transplantation on the incidence of donor-specific anti-HLA antibodies. Am J Transplant. 2016;16(9):2661-2669.
Kaneku H. 2013 annual literature review of donor-specific HLA antibodies after organ transplantation. Clin Transpl. 2013;Chapter 7, 63-75.
Tokodai K, Miyagi S, Nakanishi C, et al. Impact of the Trough Level of Calcineurin Inhibitor on the Prevalence of Donor-Specific Human Leukocyte Antigen Antibodies During Long-Term Follow-Up After Pediatric Liver Transplantation: Antibody Strength and Complement-Binding Ability. Transplant Direct. 2017;3(8):e196.
Vandevoorde K, Ducreux S, Bosch A, et al. Prevalence, risk factors, and impact of donor-specific alloantibodies after adult liver transplantation. Liver Transpl. 2018;24(8):1091-1100.
Bucuvalas JC, Ryckman FC, Arya G, et al. A novel approach to managing variation: outpatient therapeutic monitoring of calcineurin inhibitor blood levels in liver transplant recipients. J Pediatr. 2005;146(6):744-750.